

Lupin announces District Court Ruling on Ramipril

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------------	-------------------	-------------------------	--------------------------

Mumbai, 19 July 2006: Lupin Limited. announced today that the United States District Court for the Eastern District of Virginia has issued an opinion following the completion of a trial on Sanofi-Aventis' U.S. Patent No. 5061722 relating to Altace® (Ramipril) and found the patent to be valid.

Commenting on the judgment, Dr. Kamal Sharma, Managing Director of Lupin Ltd. said "It was a very close call for us and we are disappointed that the court found the patent to be valid, albeit reluctantly, in the judge's own words. We intend to appeal this decision to the Federal Circuit."

The court decision arises from a suit filed by King Pharmaceuticals and Sanofi-Aventis against the Company alleging patent infringement on the 5061722 patent listed in the FDA's Orange Book. The trial was completed in June 2006.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2006, the Company's Revenues and Profit after Tax were Rs.16,610 million (US\$ 375 million) and Rs.1,827 million (US\$ 41 million) respectively.

For further information contact:

Raju Kane

The Source

Tel. + 91 22 24901327, 24901328

Fax No. 24901325

Mobile No. +91 98200 45656

E-mail : rajukane@sourcepr.com